RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
A phase II clinical study of RC48-ADC combined with Bevacizumab as late-line treatment in
patients with HER2-expressed metastatic colorectal cancer. A total of 30 patients are planned
to be enrolled.
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University